Tilray Inc TLRY shares are trading higher following news the company purchased a majority position in amended Medmen Enterprises Inc MMNFF convertible notes for about $165.8 million.
Irwin D. Simon, Tilray's Chairman and CEO, said, "Backed by accelerating trends towards legalization globally, we are focused on building the world's leading cannabis-focused consumer branded company with a goal of $4 billion of revenue by the end of our fiscal 2024."
"The investment we are announcing in MedMen securities today, one of the most recognized brands in the $80 billion U.S. cannabis market, is a critical step towards delivering on our objective as we work to enable Tilray to lead the U.S. market when legalization allows," Simon stated.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of the company's sales are in Canada and in the international medical cannabis export market.
TLRY Price Action: The stock is trading higher by 4.2% to $13.67 after hours. Tilray has a 52-week high of $67 and a 52-week low of $4.41.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!